In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Introducing the ESC Council of Cardio-Oncology



Dear Friends,

In 2016 the Task Force for Cancer Treatment Toxicity was established and a Position Paper on this topic was published.

In spring 2017 we had the idea to move forward and founded a group inside the ESC on Cardio-Oncology. Following on from a Task Force meeting in Barcelona, it was decided to officially ask the constitution of an ESC Council of Cardio-Oncology. In August 2018 the General Assembly of the ESC definitively approved the Council of Cardio Oncology (CCO) that I have the pleasure to chair for this two year period.


Our aims are to bring together the specialists in the field and the specialists coming from Oncology, Hematology, Radiotherapy and related disciplines to enhance the knowledge and the standard of care for Cardio-Oncology patients in Europe.


We will focus our work around all the pillars of the ESC Strategic Plan: Advocacy, Congresses, Research, Membership, and Education.


Since the Council’s creation we have already been working on:

  • Proposals for the ESC Congress 2019 Scientific Programme
  • Joint sessions during EuroEcho-Imaging 2018, EHRA 2019 and HFA 2019
  • Educational initiatives
  • Survey about Cardio-Oncology in General Cardiology (December 2019)
  • A series of four articles about Cardio-Oncology topics that will be published on the E-Journal of Cardiology Practice from January 2019.


Top reasons to become a member

  1. Cardio Oncology is a relatively new subspecialty involving all fields of cardiology from ventricular dysfunction to coronary heart disease to arrhythmic issues to vascular complications. Sooner or later you will find a patient with concomitant cancer and cardiac diseases and you will need to know at least the essentials of this condition.
  2. Cancer incidence and survivorship has greatly increased, leading to a high prevalence of cancer patient survivors. The same for cardiovascular diseases. The probability to encounter patients with both conditions will become more and more frequent in your practice.
  3. The long survivorship after cancer therapy may often allow cardiovascular toxicities to spread; even many years later. . The correct diagnosis and also active screening and research of these cardiovascular conditions may be a cardiologist’s task in the near future.

Membership is free and gives access to:

  • A quarterly Newsletter
  • Member Directory
  • Access to future Educational initiatives.

Join Now

Looking forward to having you on board.
Best wishes

Dr. Riccardo Asteggiano MD FESC
Chair of the Council of Cardio-Oncology 2018-2020